Second pass at: Cost versus information: making the trade-off explicitly

Posting this under the heading it deserves: Second pass at: Cost versus information: making the trade-off explicitly Everything below is what sits behind that.

Working through the identity arithmetic and I would like it checked.

retatrutide has a monoisotopic mass close to 4731.3 Da. On an electrospray instrument I would expect to see the multiply charged series rather than the intact singly charged ion, so for the doubly charged species I calculate (4731.3 + 2 x 1.00728) / 2, and for the triply charged the analogous expression.

The observed values in the report sit within a few ppm of those. My question is what that actually establishes, because I have seen people treat a mass match as a purity result and I do not think it is one.

Lateral-flow devices: like a rapid COVID test. They have a reagent strip and produce a colour result. They are quick but not precise and not intended for quantitative work.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

False positives and false negatives: no test has 100% sensitivity and 100% specificity. A negative result does not guarantee absence; a positive result does not guarantee presence. The predictive value depends on prevalence.

Precision of home tests: most consumer-accessible devices are not precise to the level people want ("is this 99% pure or 97% pure"). They give a yes/no or a rough category, not a quantitative number.

What physical quantity does the device measure? A colorimetric or lateral-flow method typically responds to a class of chemistry rather than to a specific molecule. It can distinguish "peptide present" from "nothing present" but generally cannot distinguish the intended peptide from a closely related one.

Colorimetric tests: colour intensity correlates with concentration, but the relationship is non-linear at extremes and the correlation depends on the exact conditions (pH, temperature, timing). Reading the colour visually introduces subjectivity.

Coming back to post #6, because the follow-up matters more than the original answer.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

Immunoassay limitations: tests that use antibodies have cross-reactivity limitations. An antibody raised to semaglutide will cross-react to some degree with tirzepatide and other structurally similar compounds. The test result conflates them.

Sample handling matters: if a sample is contaminated or degraded before testing, the test gives you the result for the degraded sample, not for fresh material. That is not a failure of the test; it is the test working correctly.

Molecular tests: DNA or RNA tests are not applicable to peptides, which do not contain nucleic acids. Peptide-specific tests rely on protein recognition, not nucleic-acid detection.

Why third-party testing is stronger: a home test run by the person who made the compound is a self-selected result. The test run by a neutral third party removes obvious sources of bias.

Worth separating two things that post #9 runs together.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

post #13 is right about the mechanism and I think understates the practical bit.

Enzyme assays: if you have an enzyme that reacts specifically with your compound, an enzyme-based assay can work. These are sometimes available commercially but are less common than antibody-based tests.